| Switching patients with PNH from pegcetacoplan to iptacopan: a case series |
|
Hematology. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-Making |
|
American Journal of Hematology |
Aplastic Anemia |
| A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria |
|
International Journal of Hematology |
Aplastic Anemia |
| Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy |
|
HemaSphere |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy |
|
HemaSphere |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A Survey of Provider Practices for Diagnosis and Treatment of Pediatric Moderate Aplastic Anemia From the North American Pediatric Aplastic Anemia Consortium |
|
Journal of Pediatric Hematology/Oncology (JPHO) |
Aplastic Anemia |
| Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag |
|
The New England Journal of Medicine |
Aplastic Anemia |
| Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia |
|
The New England Journal of Medicine |
Aplastic Anemia |
